Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 10, 2015 07:30 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals Opens Phase 2a Proof-of-Concept Trial of VTP-38543 in Atopic Dermatitis Patients

FORT WASHINGTON, Pa., Dec. 10, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced updated plans to begin clinical development...
November 24, 2015 16:15 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals to Present at 27th Annual Piper Jaffray Healthcare Conference

FORT WASHINGTON, Pa., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Jeffrey Hatfield, President and Chief...
November 18, 2015 16:15 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals Announces Positive Top-Line Results From a Phase 1 Multiple Ascending Dose Trial of VTP-43742

Multiple ascending doses of VTP-43742 shown to be safe and generally well tolerated in healthy human volunteers Robust ex vivo biomarker response, suppressing secretion of...
November 12, 2015 16:30 ET | Source: Vitae Pharmaceuticals, Inc.

REMINDER: Vitae Pharmaceuticals to Host Analyst and Investor Briefing

Scheduled for 7:00 a.m. EST on November 19, 2015 Presentations to begin at 7:15 a.m. EST FORT WASHINGTON, Pa., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a...
November 10, 2015 16:30 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals to Present at Stifel 2015 Healthcare Conference

FORT WASHINGTON, Pa., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Jeffrey Hatfield, President and Chief...
November 05, 2015 16:05 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals Reports Third Quarter 2015 Operating and Financial Results

Announces psoriasis as lead indication for VTP-43742 Conference call scheduled for 4:30 p.m. EST today FORT WASHINGTON, Pa., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc....
November 02, 2015 16:30 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals to Announce Third Quarter 2015 Financial Results on November 5, 2015

FORT WASHINGTON, Pa., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, will host a conference call on Thursday, November 5, 2015 at...
October 20, 2015 08:00 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals to Host Analyst and Investor Briefing

FORT WASHINGTON, Pa., Oct. 20, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, will host an Analyst and Investor Briefing on Thursday,...
September 30, 2015 16:15 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals Appoints Dr. Karen Bernstein to Board of Directors

FORT WASHINGTON, Pa., Sept. 30, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the appointment of Karen Bernstein, Ph.D.,...
September 29, 2015 06:30 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals Initiates Second Part of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Psoriatic Patients

FORT WASHINGTON, Pa., Sept. 29, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that it has initiated the second part of its...